Last week, Louisville plastic surgeon Dr. M. Bradley Calobrace performed one of the first breast augmentation surgeries in the United States using the newly FDA-approved sixth-generation Motiva breast implant. The implant, produced by medical technology company Establishment Labs Holdings Inc., marks a significant advance in breast aesthetics.
Juan José Chacón-Quirós, founder and CEO of Establishment Labs, shared the excitement following the FDA’s approval. “We have seen a surge in demand for Motiva implants—both from surgeons and patients,” he said. The announcement coincided with the American Society of Plastic Surgeons (APS) annual meeting, where the company engaged with over 400 plastic surgeons eager to learn more about the product.
To meet rising interest, Establishment Labs doubled its national sales team, now employing 25 representatives. Chacón-Quirós expressed confidence that Motiva implants could become the preferred choice in the U.S. market, thanks to their innovative design and scientific backing.
About Establishment Labs and the Motiva Implants
Establishment Labs is a Costa Rica-based company focused on improving women’s health, particularly in breast aesthetics and reconstruction. The Motiva implants recently approved by the FDA include the Motiva® SmoothSilk® Ergonomix and the Motiva SmoothSilk Round. These implants are approved for both primary breast augmentations and revision surgeries.
Dr. Calobrace, alongside New Jersey board-certified plastic surgeon Dr. Caroline A. Glicksman, was among the first to perform surgeries with these implants in the U.S. Dr. Calobrace noted, “I have many patients who have been waiting, some for years, for Motiva approval. I am excited to perform the first Motiva breast augmentations in the U.S. These devices not only improve aesthetics but also significantly reduce complication rates compared to other implants. Motiva implants are going to be a game changer.”
Features of the Sixth-Generation Motiva Implants
The Motiva implants feature a SmoothSilk surface designed to improve biocompatibility and reduce inflammation risk. The two implant styles offer distinct benefits:
Motiva SmoothSilk Ergonomix: The world’s first ergonomic breast implant that mimics natural breast tissue. It changes shape according to body posture, appearing round when lying down and teardrop-shaped when standing.
Motiva SmoothSilk Round: Designed to enhance fullness and softness in the upper breast area while maintaining a consistent rounded shape regardless of posture.
Expert Endorsements and Clinical Background
Dr. Glicksman, Medical Director of the Motiva U.S. IDE Study and clinical trial investigator, emphasized the implant’s importance: “The plastic surgery community has waited more than a decade to offer a truly new product to breast augmentation patients in the U.S. We can now confidently offer patients an implant that has consistently demonstrated low complication rates and high patient satisfaction.”
Dr. Calobrace is a board-certified plastic surgeon and a respected member of multiple professional societies, including the American Society of Plastic Surgeons. He also serves on the clinical faculty at the University of Louisville and the University of Kentucky, where he has earned multiple teaching honors.
Establishment Labs’ Global Impact
Since its founding in 2010, Establishment Labs has delivered nearly four million Motiva devices worldwide. The company is recognized for raising safety and patient satisfaction standards in more than 85 countries. Its product line spans breast health, aesthetics, and reconstruction, leveraging science and technology to improve women’s well-being globally.
Related topics:
- Mom Revives Daughter’s Traditions After Mastectomy
- Brittany Cartwright Teases New Breast Augmentation
- “Sentinel”Helps 22 Women Avoid Mastectomy At UCCK
